appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Suven Life Sciences Ltd
SUVEN
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Suven Life Sciences Limited is a bio-pharmaceutical company, engaged in the business of manufacture and sale of bulk drugs and intermediaries.
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Updates
Suven Life Sciences Limited has informed the Exchange regarding 'Suven Life Sciences to Present Positive Results from Phase-2a Proof-of-Concept Study of Ropanicant (SUVN-911) and Updates on Innovation Pipeline Assets at Neuroscience 2024, Chicago, USA'. | Download
Suven Life Sciences Limited has informed the Exchange regarding 'Suven Life Sciences to Present Positive Results from Phase-2a Proof-of-Concept Study of Ropanicant (SUVN-911) and Updates on Innovation Pipeline Assets at Neuroscience 2024, Chicago, USA'. | Download
Cash Dividend
Interim • Div/Share: ₹ 1
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant